Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.32
HZNP's Cash-to-Debt is ranked lower than
81% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. HZNP: 0.32 )
Ranked among companies with meaningful Cash-to-Debt only.
HZNP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.91 Max: N/A
Current: 0.32
Equity-to-Asset 0.28
HZNP's Equity-to-Asset is ranked lower than
90% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. HZNP: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
HZNP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.44 Max: 0.7
Current: 0.28
-0.77
0.7
Piotroski F-Score: 2
Altman Z-Score: 0.21
Beneish M-Score: -2.71
WACC vs ROIC
4.86%
-6.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -22.60
HZNP's Operating Margin % is ranked lower than
79% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. HZNP: -22.60 )
Ranked among companies with meaningful Operating Margin % only.
HZNP' s Operating Margin % Range Over the Past 10 Years
Min: -1841.5  Med: -57.9 Max: 7.31
Current: -22.6
-1841.5
7.31
Net Margin % -21.26
HZNP's Net Margin % is ranked lower than
80% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. HZNP: -21.26 )
Ranked among companies with meaningful Net Margin % only.
HZNP' s Net Margin % Range Over the Past 10 Years
Min: -1635.12  Med: -201.31 Max: 5.22
Current: -21.26
-1635.12
5.22
ROE % -16.40
HZNP's ROE % is ranked lower than
77% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. HZNP: -16.40 )
Ranked among companies with meaningful ROE % only.
HZNP' s ROE % Range Over the Past 10 Years
Min: -523.78  Med: -107.35 Max: 4.27
Current: -16.4
-523.78
4.27
ROA % -5.75
HZNP's ROA % is ranked lower than
74% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. HZNP: -5.75 )
Ranked among companies with meaningful ROA % only.
HZNP' s ROA % Range Over the Past 10 Years
Min: -186.55  Med: -59.51 Max: 1.89
Current: -5.75
-186.55
1.89
ROC (Joel Greenblatt) % -424.00
HZNP's ROC (Joel Greenblatt) % is ranked lower than
86% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. HZNP: -424.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HZNP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82  Med: -2263.21 Max: 520.88
Current: -424
-7948.82
520.88
3-Year Revenue Growth Rate 73.80
HZNP's 3-Year Revenue Growth Rate is ranked higher than
97% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. HZNP: 73.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HZNP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 115.5
Current: 73.8
0
115.5
3-Year EPS without NRI Growth Rate -23.70
HZNP's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. HZNP: -23.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HZNP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -52 Max: -23.7
Current: -23.7
GuruFocus has detected 4 Warning Signs with Horizon Pharma PLC $HZNP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HZNP's 30-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

HZNP Guru Trades in Q2 2016

Julian Robertson 894,577 sh (+3.01%)
Steve Mandel Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Ken Heebner Sold Out
RS Investment Management Sold Out
Steven Cohen 359,800 sh (-64.70%)
» More
Q3 2016

HZNP Guru Trades in Q3 2016

Paul Tudor Jones 49,605 sh (New)
Ken Heebner 1,000,000 sh (New)
Steven Cohen 509,400 sh (+41.58%)
Julian Robertson 673,933 sh (-24.66%)
» More
Q4 2016

HZNP Guru Trades in Q4 2016

Joel Greenblatt 126,466 sh (New)
Paul Tudor Jones 104,075 sh (+109.81%)
Ken Heebner 1,530,000 sh (+53.00%)
Julian Robertson 793,933 sh (+17.81%)
Steven Cohen 572,900 sh (+12.47%)
» More
Q1 2017

HZNP Guru Trades in Q1 2017

Julian Robertson Sold Out
Ken Heebner Sold Out
Steven Cohen 427,200 sh (-25.43%)
Joel Greenblatt 37,797 sh (-70.11%)
Paul Tudor Jones 20,100 sh (-80.69%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:SUPN, OTCPK:EVTCY, NAS:RDUS, NAS:PCRX, NAS:PAHC, OTCPK:SWPIF, NAS:EGRX, NYSE:DPLO, NAS:IPXL, NAS:MNTA, OTCPK:KHTRF, OTCPK:NPPNY, OTCPK:TWMJF, NAS:SGYP, NAS:INNL, NAS:IRWD, NAS:ENDP, NAS:HRTX, NYSE:LCI, NAS:AMPH » details
Traded in other countries:HPR.Germany,
Headquarter Location:Ireland
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Horizon Pharma is a specialty and generic drug manufacturing company. The company is focused on the identification, development, acquisition, and commercialization of differentiated and accessible medicines that address unmet medical needs. The overwhelming majority of revenue is generated in the United States. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Horizon Pharma PLC

Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farm
Horizon Pharma plc Announces District Court Decision to Uphold PENNSAID® (diclofenac sodium topical solution) 2% w/w Patent
Horizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare Businesswomen's Association Luminary
Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older
Horizon Pharma plc to Host First-Quarter 2017 Conference Call and Webcast on May 8, 2017
Horizon Pharma plc Named One of the Best Workplaces in Health Care by Great Place to Work® and Fortune Magazine
Horizon Pharma plc Named to the Crain’s Chicago Business 2017 “Best Places To Work” List
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO® (naproxen/esomeprazole) Delayed Release Tablets

Will Represent the Sixteenth U.S. Patent Listed in the Orange Book for VIMOVO

DUBLIN, Ireland, March 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 15/180,173, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets.
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The term of the U.S. patent scheduled to issue from this application will expire May 31, 2022. After issuance, Horizon and a subsidiary of Aralez Pharmaceuticals Inc. (ARLZ) (TSX:ARZ) plan to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. About VIMOVO
VIMOVO (naproxen/esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not interchangeable with the individual components of naproxen and esomeprazole magnesium.
VIMOVO is not recommended for use in children younger than 18 years of age. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond six months. VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by your health care provider. For Full Prescribing Information please see www.VIMOVO.com. Important Safety Information Nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen, a component of VIMOVO, may increase the chance of a heart attack or stroke, which can be fatal. This chance increases with longer use and in people who have heart disease or risk factors for heart disease.
 VIMOVO should not be used before or after a type of heart surgery called coronary artery bypass graft (CABG).
 NSAID-containing medications like VIMOVO may increase the chance of stomach and intestinal problems, such as bleeding or an ulcer.  These problems can happen without warning and can lead to death. Older patients may have a greater chance of developing these problems. VIMOVO is not right for everyone, including patients who have had an asthma attack, hives or other allergic reaction with aspirin or any other NSAID medicine, patients who are allergic to any of the ingredients in VIMOVO or women in late stages of pregnancy. Serious allergic reactions, including skin reactions, can occur without warning and can be life-threatening; discontinue use of VIMOVO at the first appearance of a skin rash or if you develop sudden wheezing; swelling of the lips, tongue or throat; fainting or problems swallowing. VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by your health care provider. Tell your health care provider right away if you develop signs of active bleeding from any source. VIMOVO can lead to onset of new hypertension or worsening of existing high blood pressure, either of which may contribute to an increased risk of a heart attack or stroke. Speak with your health care provider before starting VIMOVO if you Have a history of ulcers or bleeding in the stomach or intestinesHave heart problems, high blood pressure, or are taking high blood pressure medicationsHave kidney or liver problems Tell your doctor about all of the medicines you take, prescription and non-prescription drugs, including clopidogrel, vitamins and herbal supplements. VIMOVO may affect how other medicines work and other medicines may affect how VIMOVO works. VIMOVO may increase your risk of getting severe diarrhea. Call your doctor right away if you have watery stool, stomach pain and fever that does not go away. Talk to your health care provider about your risk for bone fractures and developing low levels of magnesium if you take VIMOVO for a long period of time. Talk to your health care provider about your risk for developing low levels of magnesium if you take VIMOVO for a long period of time. The most common side effects of VIMOVO include: inflammation of the lining of the stomach, indigestion, diarrhea, stomach ulcers, abdominal pain and nausea. For more information on VIMOVO, please see the Medication Guide and Full Prescribing Information. About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page. Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the issuance of a patent based on the Notice of Allowance from the U.S. Patent and Trademark Office, the expected term of the patent, if issued, potential patent protection for VIMOVO and plans to list any newly issued patent in the FDA's Orange Book. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether the administrative processes required for the issuance of a patent as indicated in the Notice of Allowance will be completed in a timely matter or at all, whether the patent, if issued as indicated in the Notice of Allowance, will provide sufficient protection and market exclusivity for VIMOVO, whether any patents covering VIMOVO may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.
Contacts:
Investors:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]

U.S. Media:
Geoff Curtis
Senior Vice President, Corporate Communications
[email protected]

Ireland Media:
Ray Gordon
Gordon MRM
[email protected]

Read more...
Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years

DUBLIN, Ireland, March 22, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the presentation of new data on the use of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in children living with urea cycle disorders (UCD) two months to two years of age.  These data will be presented on Thursday, March 23 at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Phoenix, Arizona.
The study results are from two clinical trials that enrolled children with UCDs aged two months to less than two years.  Study participants were predominantly on relatively stable doses of sodium phenylbutyrate and switched to equivalent doses of RAVICTI.  The primary outcomes measured in the study were targeted mean normalized plasma ammonia of less than 100 μmol/L, hyperammonemic crises (HACs) and adverse events (AEs).  Safety and efficacy was also evaluated after patients transitioned to RAVICTI. “The RAVICTI development program is part of our overall approach to reinvest in our medicines for people living with rare diseases,” said Jeffrey W. Sherman, M.D., FACP, executive vice president, research and development and chief medical officer, Horizon Pharma plc.  “While UCDs are very rare and can be devastating, continued advancements in diagnosis and ongoing studies evaluating management options are helping improve the long-term outcome of people living with the disorder.” RAVICTI is currently indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients two years of age or greater with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  RAVICTI is not indicated for patients less than two years of age.  In June 2016, Horizon submitted a supplemental New Drug Applications (sNDA) with the U.S. Food and Drug Administration (FDA) seeking to expand the approved age range for RAVICTI to include children as young as two months of age. The poster presentation (abstract #2873; poster #71), entitled “Safety and Efficacy of Glycerol Phenylbutyrate for Management of Urea Cycle Disorders in Patients Aged 2 Months to 2 Years,” will be presented on Thursday, March 23, 2017 from 10:00 a.m. – 11:30 a.m. at the ACMG Annual Meeting. About Urea Cycle Disorders
A UCD is a rare genetic disorder that affects approximately 1 in 35,000 live births in the United States.  It is caused by an enzyme deficiency in the urea cycle, a process that is responsible for converting excess ammonia from the bloodstream and ultimately removing it from the body.  Because of this, people with a UCD experience hyperammonemia, or elevated ammonia levels in their blood that can then reach the brain where it can cause irreversible brain damage, coma or death.  UCD symptoms may first occur at any age depending on the severity of the disorder, with more severe defects presenting earlier in life.1 About RAVICTI
In the U.S., RAVICTI was approved in February 2013 and is indicated for the chronic management of adult and pediatric patients ≥2 years of age with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). Important Safety Information LIMITATIONS OF USE RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.The use of RAVICTI in patients <2 months of age is contraindicated. CONTRAINDICATIONS:
RAVICTI is contraindicated in patients: Less than 2 months of age. Children <2 months of age may have immature pancreatic exocrine function, which could impair hydrolysis of RAVICTI, leading to impaired absorption of phenylbutyrate and hyperammonemia.With known hypersensitivity to phenylbutyrate. Signs of hypersensitivity include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. WARNINGS AND PRECAUTIONS Neurotoxicity: Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels ≥500 µg/mL. Reduce RAVICTI dosage if symptoms of neurotoxicity, including vomiting, nausea, headache, somnolence, confusion, or sleepiness, are present in the absence of high ammonia or other intercurrent illnesses.Reduced Phenylbutyrate Absorption in Pancreatic Insufficiency or Intestinal Malabsorption: Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely. USE IN SPECIFIC POPULATIONS Pregnancy: RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data, RAVICTI may cause fetal harm. A voluntary patient registry will include evaluation of pregnancy outcomes in patients with UCDs. For more information regarding the registry program, visit www.ucdregistry.com or call 1-855-823-2595.Nursing Mothers: Caution should be exercised when administering RAVICTI to nursing mothers, as breastfeeding is not recommended with maternal use of RAVICTI. It is not known whether RAVICTI or its metabolites are present in breast milk. ADVERSE REACTIONS                  Adverse reactions occurring in ≥10% of adult patients during short-term treatment (n=44, 4 weeks) with RAVICTI were diarrhea, flatulence, and headache.Adverse reactions occurring in ≥10% of adult patients during long-term treatment (n=51, 12 months) with RAVICTI were nausea, vomiting, diarrhea, decreased appetite, hyperammonemia, dizziness, headache, and fatigue.Adverse reactions occurring in ≥10% of pediatric patients during long-term treatment (n=26, 12 months) with RAVICTI were upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, hyperammonemia, and headache. DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level. Monitor ammonia levels closely.Probenecid: May affect renal excretion of metabolites of RAVICTI, including PAGN and PAA. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see the Full Prescribing Information and Medication Guide for RAVICTI. About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page. References: Ah Mew N, Lanpher BC, Gropman A, et al.; Urea Cycle Disorders Consortium. Urea Cycle Disorders Overview. 2003 Apr 29 [Updated 2015 Apr 9]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1217/

Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]

U.S. Media Contact:
Matt Flesch
Executive Director, Product Communications
[email protected]

Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 4.93
HZNP's Forward PE Ratio is ranked higher than
90% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. HZNP: 4.93 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 11.00
HZNP's Price-to-Owner-Earnings is ranked higher than
85% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. HZNP: 11.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HZNP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.95  Med: 20.04 Max: 31.44
Current: 11
10.95
31.44
PB Ratio 1.37
HZNP's PB Ratio is ranked higher than
68% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. HZNP: 1.37 )
Ranked among companies with meaningful PB Ratio only.
HZNP' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.22 Max: 14.94
Current: 1.37
0.8
14.94
PS Ratio 1.65
HZNP's PS Ratio is ranked higher than
56% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. HZNP: 1.65 )
Ranked among companies with meaningful PS Ratio only.
HZNP' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 4.22 Max: 19
Current: 1.65
1.47
19
Price-to-Free-Cash-Flow 5.03
HZNP's Price-to-Free-Cash-Flow is ranked higher than
91% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. HZNP: 5.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HZNP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.01  Med: 10.09 Max: 433
Current: 5.03
5.01
433
Price-to-Operating-Cash-Flow 4.89
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
87% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. HZNP: 4.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HZNP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 9.58 Max: 209.52
Current: 4.89
4.87
209.52
EV-to-EBIT -13.05
HZNP's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. HZNP: -13.05 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.8 Max: 219.8
Current: -13.05
-775.4
219.8
EV-to-EBITDA 169.67
HZNP's EV-to-EBITDA is ranked lower than
88% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. HZNP: 169.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.3 Max: 518
Current: 169.67
-608
518
Current Ratio 1.67
HZNP's Current Ratio is ranked lower than
67% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. HZNP: 1.67 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.99 Max: 4.39
Current: 1.67
0.16
4.39
Quick Ratio 1.48
HZNP's Quick Ratio is ranked lower than
63% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. HZNP: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.73 Max: 4.27
Current: 1.48
0.16
4.27
Days Inventory 132.65
HZNP's Days Inventory is ranked lower than
58% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. HZNP: 132.65 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 59.25 Max: 184.95
Current: 132.65
13.1
184.95
Days Sales Outstanding 145.22
HZNP's Days Sales Outstanding is ranked lower than
75% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. HZNP: 145.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 90.85 Max: 145.22
Current: 145.22
67.08
145.22
Days Payable 70.36
HZNP's Days Payable is ranked lower than
69% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. HZNP: 70.36 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 27.59  Med: 183.99 Max: 410.36
Current: 70.36
27.59
410.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.70
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. HZNP: -34.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HZNP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1  Med: -61.1 Max: 0
Current: -34.7
-428.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.83
HZNP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. HZNP: 0.83 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HZNP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 3.23 Max: 29.51
Current: 0.83
0
29.51
Price-to-Median-PS-Value 0.39
HZNP's Price-to-Median-PS-Value is ranked higher than
89% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. HZNP: 0.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HZNP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.04 Max: 2.83
Current: 0.39
0
2.83
Earnings Yield (Greenblatt) % -7.66
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. HZNP: -7.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HZNP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.68  Med: 0.8 Max: 2.6
Current: -7.66
-7.68
2.6

More Statistics

Revenue (TTM) (Mil) $997.3
EPS (TTM) $ -1.32
Beta1.19
Short Percentage of Float8.45%
52-Week Range $9.45 - 23.44
Shares Outstanding (Mil)162.71

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,266 1,407 1,515
EPS ($) 2.10 2.60 3.40
EPS without NRI ($) 2.10 2.60 3.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:HZNP

Headlines

Articles On GuruFocus.com
Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine May 23 2017 
Horizon Pharma plc Announces District Court Decision to Uphold PENNSAID® (diclofenac sodium topic May 15 2017 
Horizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare Businesswomen's Association Lumin May 11 2017 
Investors: Covered Call reports for Horizon Pharma, JD.com, JP Morgan Chase, Kite Pharma and Micron May 09 2017 
Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (R May 08 2017 
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbu May 01 2017 
Horizon Pharma plc to Host First-Quarter 2017 Conference Call and Webcast on May 8, 2017 Apr 13 2017 
Horizon Pharma plc Named One of the Best Workplaces in Health Care by Great Place to Work® and Fo Apr 12 2017 
Horizon Pharma plc Named to the Crain’s Chicago Business 2017 “Best Places To Work” L Apr 07 2017 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice o Mar 30 2017 

More From Other Websites
Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine... May 23 2017
Julian Robertson's Tiger Mgmt Sold Apple and Google, Bought Adobe in Q1 May 22 2017
Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with... May 15 2017
Nuvo Pharmaceuticals™ Announces District Court Decision to Uphold U.S. Pennsaid® 2% Patent May 15 2017
Horizon Pharma plc Announces District Court Decision to Uphold PENNSAID® (diclofenac sodium topical... May 15 2017
Edited Transcript of HZNP earnings conference call or presentation 8-May-17 11:30am GMT May 12 2017
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting May 11 2017
ETFs with exposure to Horizon Pharma Plc : May 11, 2017 May 11 2017
Horizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare Businesswomen's Association... May 11 2017
Nuvo Pharmaceuticals™ Announces 2017 First Quarter Results May 10 2017
Pharma Lobby Ousts 22 Drugmakers Amid U.S. Pricing Debate May 09 2017
Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed May 09 2017
Horizon Pharma, Inc. -- Moody's affirms Horizon Pharma; revises outlook to negative May 09 2017
Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : May 9, 2017 May 09 2017
Today's Research Reports on Stocks to Watch: Horizon Pharma and PTC Therapeutics May 09 2017
Why Liberty Global, Horizon Pharma, and Synchronoss Technologies Slumped Today May 08 2017
These Drugmakers Plunged On Consensus-Lagging Q1 Sales, Losses May 08 2017
Here's Why Shares of Horizon Pharma (HZNP) are Cratering Today May 08 2017
Why Horizon Pharma plc Stock Is Crashing Today May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat